This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEB7Q0U9_M.jpg
Each unit sold in the placement consists of one common share and a half-warrant. Investors holding these warrants are given the opportunity to purchase an additional common share at a price of CAD0.41 (USD1 = CAD1.3556) until December 4, 2026. This offer provides an incentive for investment while potentially increasing the company’s capital in the future if the warrants are exercised.
In connection with securing subscriptions for the placement, finders were compensated with CAD29,977.50 and received finder’s warrants. The exact date of this arrangement was not specified, but it forms part of the overall strategy to attract investors to the placement.
The securities issued are subject to a standard four-month hold period and are pending approval from the Toronto Stock Exchange. This regulatory step is customary for such transactions and ensures compliance with market standards.
The completion of this private placement represents a key financial milestone for Avicanna, as it seeks to advance its research and development initiatives in the biopharmaceutical sector. The funds raised will likely contribute to ongoing projects and corporate activities aimed at developing cannabinoid-based products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
